|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miller YE: Pathogenesis of lung cancer:
100 year report. Am J Respir Cell Mol Biol. 33:216–223. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Adams JM, Difazio LT, Rolandelli RH, Luján
JJ, Haskó G, Csóka B, Selmeczy Z and Németh ZH: HIF-1: A key
mediator in hypoxia. Acta Physiol Hung. 96:19–28. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takasaki C, Kobayashi M, Ishibashi H,
Akashi T and Okubo K: Expression of hypoxia-inducible factor-1α
affects tumor proliferation and antiapoptosis in surgically
resected lung cancer. Mol Clin Oncol. 5:295–300. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang SL, Ren QG, Wen L and Hu JL:
Clinicopathological and prognostic significance of
hypoxia-inducible factor-1 alpha in lung cancer: A systematic
review with meta-analysis. J Huazhong Univ Sci Technolog Med Sci.
36:321–327. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ren W, Mi D, Yang K, Cao N, Tian J, Li Z
and Ma B: The expression of hypoxia-inducible factor-1α and its
clinical significance in lung cancer: A systematic review and
meta-analysis. Swiss Med Wkly. 143:w138552013.PubMed/NCBI
|
|
8
|
Cha ST, Chen PS, Johansson G, Chu CY, Wang
MY, Jeng YM, Yu SL, Chen JS, Chang KJ, Jee SH, et al: MicroRNA-519c
suppresses hypoxia-inducible factor-1alpha expression and tumor
angiogenesis. Cancer Res. 70:2675–2685. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ding G, Huang G, Liu HD, Liang HX, Ni YF,
Ding ZH, Ni GY and Hua HW: MiR-199a suppresses the hypoxia-induced
proliferation of non-small cell lung cancer cells through targeting
HIF1α. Mol Cell Biochem. 384:173–180. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wei X, Wang C, Ma C, Sun W, Li H and Cai
Z: Long noncoding RNA ANRIL is activated by hypoxia-inducible
factor-1α and promotes osteosarcoma cell invasion and suppresses
cell apoptosis upon hypoxia. Cancer Cell Int. 16:732016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang C, Liu S, Wang H, Zhang Z, Yang Q
and Gao F: LncRNA PVT1 overexpression is a poor prognostic
biomarker and regulates migration and invasion in small cell lung
cancer. Am J Transl Res. 8:5025–5034. 2016.PubMed/NCBI
|
|
12
|
Wan L, Sun M, Liu GJ, Wei CC, Zhang EB,
Kong R, Xu TP, Huang MD and Wang ZX: Long noncoding RNA PVT1
promotes non-small cell lung cancer cell proliferation through
epigenetically regulating LATS2 expression. Mol Cancer Ther.
15:1082–1094. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cui D, Yu CH, Liu M, Xia QQ, Zhang YF and
Jiang WL: Long non-coding RNA PVT1 as a novel biomarker for
diagnosis and prognosis of non-small cell lung cancer. Tumour Biol.
37:4127–4134. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Conte F, Fiscon G, Chiara M, Colombo T,
Farina L and Paci P: Role of the long non-coding RNA PVT1 in the
dysregulation of the ceRNA-ceRNA network in human breast cancer.
PLoS One. 12:e01716612017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Harris AL: Hypoxia-a key regulatory factor
in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guerin E, Raffelsberger W, Pencreach E,
Maier A, Neuville A, Schneider A, Bachellier P, Rohr S, Petitprez
A, Poch O, et al: In vivo topoisomerase I inhibition attenuates the
expression of hypoxia-inducible factor 1α target genes and
decreases tumor angiogenesis. Mol Med. 18:83–94. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li L, Lin X, Shoemaker AR, Albert DH,
Fesik SW and Shen Y: Hypoxia-inducible factor-1 inhibition in
combination with temozolomide treatment exhibits robust antitumor
efficacy in vivo. Clin Cancer Res. 12:4747–4754. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tang CM and Yu J: Hypoxia-inducible
factor-1 as a therapeutic target in cancer. J Gastroenterol
Hepatol. 28:401–405. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rane S, He M, Sayed D, Vashistha H,
Malhotra A, Sadoshima J, Vatner DE, Vatner SF and Abdellatif M:
Downregulation of miR-199a derepresses hypoxia-inducible
factor-1alpha and Sirtuin 1 and recapitulates hypoxia
preconditioning in cardiac myocytes. Circ Res. 104:879–886. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cui M, Xiao Z, Wang Y, Zheng M, Song T,
Cai X, Sun B, Ye L and Zhang X: Long noncoding RNA HULC modulates
abnormal lipid metabolism in hepatoma cells through an
miR-9-mediated RXRA signaling pathway. Cancer Res. 75:846–857.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Quagliata L, Matter MS, Piscuoglio S,
Arabi L, Ruiz C, Procino A, Kovac M, Moretti F, Makowska Z,
Boldanova T, et al: Long noncoding RNA HOTTIP/HOXA13 expression is
associated with disease progression and predicts outcome in
hepatocellular carcinoma patients. Hepatology. 59:911–923. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Takahashi Y, Sawada G, Kurashige J, Uchi
R, Matsumura T, Ueo H, Takano Y, Eguchi H, Sudo T, Sugimachi K, et
al: Amplification of PVT-1 is involved in poor prognosis via
apoptosis inhibition in colorectal cancers. Br J Cancer.
110:164–171. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guan Y, Kuo WL, Stilwell JL, Takano H,
Lapuk AV, Fridlyand J, Mao JH, Yu M, Miller MA, Santos JL, et al:
Amplification of PVT1 contributes to the pathophysiology of ovarian
and breast cancer. Clin Cancer Res. 13:5745–5755. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Grampp S, Platt JL, Lauer V, Salama R,
Kranz F, Neumann VK, Wach S, Stöhr C, Hartmann A, Eckardt KU, et
al: Genetic variation at the 8q24.21 renal cancer susceptibility
locus affects HIF binding to a MYC enhancer. Nat Commun.
7:131832016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Salmena L, Poliseno L, Tay Y, Kats L and
Pandolfi PP: A ceRNA hypothesis: The Rosetta Stone of a hidden RNA
language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sumazin P, Yang X, Chiu HS, Chung WJ, Iyer
A, Llobet-Navas D, Rajbhandari P, Bansal M, Guarnieri P, Silva J
and Califano A: An extensive microRNA-mediated network of RNA-RNA
interactions regulates established oncogenic pathways in
glioblastoma. Cell. 147:370–381. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Karreth FA, Tay Y, Perna D, Ala U, Tan SM,
Rust AG, DeNicola G, Webster KA, Weiss D, Perez-Mancera PA, et al:
In vivo identification of tumor-suppressive PTEN ceRNAs in an
oncogenic BRAF-induced mouse model of melanoma. Cell. 147:382–395.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hsu SD, Tseng YT, Shrestha S, Lin YL,
Khaleel A, Chou CH, Chu CF, Huang HY, Lin CM, Ho SY, et al:
miRTarBase update 2014: An information resource for experimentally
validated miRNA-target interactions. Nucleic Acids Res.
42:(Database Issue). D78–D85. 2014. View Article : Google Scholar : PubMed/NCBI
|
